For the latest updates on our ongoing response to COVID-19, please click here.

Company Statements

Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025

Foster City, Calif. – April 4, 2019 – Gilead Sciences, Inc. announced that it has joined more than 500 of the world’s leading companies in committing to reduce greenhouse gas (GHG) emissions. Climate change, intensified by GHG emissions, poses a major threat to the health of populations and environments worldwide.

“Science is at the core of Gilead’s business, and the science of climate change is clear,” said Joydeep Ganguly, Senior Vice President, Corporate Operations. “At Gilead, we recognize the urgency to mitigate the threat of climate change and are committed to doing our part to transition to a low-carbon future. We believe that protecting the environment is integral to our mission, which is why we continuously strive to improve our environmental practices through conservation and pollution-prevention principles.”

The impact of climate change on underserved and at-risk populations has enormous implications for global health. These include increased transmission of serious diseases, compounding health risks for the young and elderly, and greater danger for those already immunocompromised. Gilead stands by our patients, at-risk populations and the environment through an ambitious GHG strategy.

In line with the Paris Agreement’s central aim of keeping the global temperature rise below 2 degrees Celsius this century, we have committed to reducing our global scope 1 and 2 greenhouse gas emissions by 25 percent by 2025, compared with a 2016 baseline. To meet this goal, we have developed a multi-year plan that includes procuring renewable energy for locations where we will have the greatest impact and applying energy efficient technologies and measures to improve the performance of our facilities.

We are also committed to external annual reporting of our scope 1 and 2 emissions and the progress we are making ahead of 2025. Our scope 1 and 2 emissions are calculated in accordance with the World Resources Institute (WRI)/World Business Council for Sustainable Development (WBCSD) Greenhouse Gas Protocol Corporate Standard and are verified by a certified assurance provider using the International Organization for Standardization (ISO) 14064-3 standard for greenhouse gas assertions. Our reporting boundary includes all sites for which Gilead maintains operational control during the reporting period.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Forward-Looking Statement

This company statement includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of that Gilead may be unable to reduce its GHG emissions and report its Scope 1 and 2 emissions as anticipated. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.